研究文章
SOX2的效用和AGR2生物标志物的早期预测三苯氧胺耐药性雌激素受体阳性乳腺癌患者
表2
对比研究这两个标记SOX2和Her2neu AGR2 ki67表达三个研究小组。
|
|
组1 (n= 124) |
组2 (n= 48) |
组3 (n= 52) |
团体的考验。 |
|
|
| SOX2 |
|
|
|
|
|
| 负 |
42 (33.9%) |
0 (0.0%) |
0 (0.0%) |
X2= 41.687 |
< 0.001 |
| 积极的 |
82例(66.1%) |
48 (100.0%) |
52 (100.0%) |
| SOX2得分 |
|
|
|
|
|
| 负 |
42 (33.9%) |
0 (0.0%) |
0 (0.0%) |
X2= 191.275 |
< 0.001 |
| 低 |
82例(66.1%) |
5 (10.4%) |
4 (7.7%) |
| 高 |
0 (0.0%) |
43 (89.6%) |
48 (92.3%) |
| AGR2 |
|
|
|
|
|
| 负 |
39 (31.5%) |
0 (0.0%) |
0 (0.0%) |
X2= 38.082 |
< 0.001 |
| 积极的 |
85例(68.5%) |
48 (100.0%) |
52 (100.0%) |
| AGR2score |
|
|
|
|
|
| 负 |
39 (31.5%) |
0 (0.0%) |
0 (0.0%) |
X2= 225.905 |
< 0.001 |
| 低 |
85例(68.5%) |
5 (10.4%) |
6 (11.5%) |
| 高 |
0 (0.0%) |
43 (89.6%) |
46 (88.5%) |
| 血清AGR2水平 |
|
|
|
|
|
| 平均数±标准差。 |
12±9.1 |
141±55.2 |
156.8±44.7 |
H= 152.495 |
< 0.001 |
| 中值(最小-最大)。 |
7 (2-32) |
130 (4 - 228) |
159.5 (9 - 236) |
| Her2neu |
|
|
|
|
|
| 负 |
87例(70.2%) |
31 (64.6%) |
31 (59.6%) |
X2= 1.932 |
0.381 |
| 积极的 |
37 (29.8%) |
17 (35.4%) |
21 (40.4%) |
| Her2neu得分 |
|
|
|
|
|
| 0 |
43 (34.7%) |
15 (31.3%) |
14 (26.9%) |
X2= 2.105 |
0.910 |
| + 1 |
44 (35.5%) |
16 (33.3%) |
17 (32.7%) |
| + 2 |
20 (16.1%) |
9 (18.8%) |
11 (21.2%) |
| + 3 |
17 (13.7%) |
8 (16.7%) |
10 (19.2%) |
| Ki67指数 |
|
|
|
|
|
| 平均数±标准差。 |
16.1±9.7 |
14.7±9.4 |
17.8±10 |
H= 2.432 |
0.296 |
| 中值(最小-最大)。 |
15 (3.8 -40) |
13 (4-38) |
16.5 (3.8 -40) |
|
|
χ
2:卡方检验, H克鲁斯卡尔-沃利斯检验:H。 统计学意义的
。
|
